TITLE

Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study

AUTHOR(S)
Fidder, H.; Schnitzler, F.; Ferrante, M.; Noman, M.; Katsanos, K.; Segaert, S.; Henckaerts, L.; Van Assche, G.; Vermeire, S.; Rutgeerts, P.
PUB. DATE
April 2009
SOURCE
Gut;Apr2009, Vol. 58 Issue 4, p501
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background and aims: This study evaluates the long-term safety of infliximab in patients with inflammatory bowel disease (IBD) treated with the drug over a 14-year period. Methods: The medical records of 734 patients with IBD treated with infliximab and 666 control patients not treated with infliximab were reviewed for adverse events. The time of onset and outcome, severity and concomitant medication were recorded. Results: Patients and controls were followed up for serious adverse events for a median time of 58 months (IQR 33-88) and 144 months (IQR 83-163), respectively. 112 severe adverse events occurred in 93 patients (13%) treated with infliximab and 157 occurred in 126 (19%) control patients (OR 1.33 (95% CI 0.56 to 3.00, p = 0.45). There was no difference between the two groups in mortality, malignancies and infection rate. Tuberculosis was diagnosed in two patients receiving infliximab who had negative skin tests at baseline whereas none of 16 patients with positive skin tests who received prophylaxis developed tuberculosis. Concomitant treatment with steroids was the only independent risk factor for infections in patients treated with infliximab (OR 2.69 (95% CI 1.18 to 6.12), p = 0.018). The most commonly observed systemic side effects were skin eruptions including psoriasiform eruptions in 150 patients (20%). Conclusions: Long-term infliximab treatment had a good overall safety profile in the patient cohort studied.
ACCESSION #
45646933

 

Related Articles

  • Anti-TNF therapy for paediatric IBD: the Scottish national experience. Cameron, F. L.; Wilson, M. L.; Basheer, N.; Jamison, A.; McGrogan, P.; Bisset, W. M.; Gillett, P. M.; Russell, R. K.; Wilson, D. C. // Archives of Disease in Childhood;Apr2015, Vol. 100 Issue 4, p399 

    Background: and aims Biological agents are being increasingly used in the UK for paediatric-onset inflammatory bowel disease (PIBD) despite limited evidence and safety concerns. We evaluated effectiveness and safety in the clinical setting, highlighting drug cost pressures, using our national...

  • Infliximab.  // Reactions Weekly;Dec2015, Vol. 1580 Issue 1, p212 

    The article describes the cases of several inflammatory bowel disease patients who experienced adverse reactions to infliximab, including diffuse erythemia with pruritus, facial erythema and erythema at infusion site.

  • Infliximab/methotrexate.  // Reactions Weekly;Sep2015, Vol. 1568 Issue 1, p166 

    The article presents a case study of a female patient who developed cerebral toxoplasmosis following the administration of infliximab and methotrexate.

  • Infliximab.  // Reactions Weekly;Sep2015, Vol. 1568 Issue 1, p164 

    The article presents a case study of a 51-year old female patient who developed posterior reversible encephalopathy syndrome following treatment with infliximab.

  • Infliximab.  // Reactions Weekly;Sep2015, Vol. 1568 Issue 1, p163 

    The article presents a case study of a 44-year old female patient who developed neurosarcoidosis during treatment with infliximab.

  • Infliximab.  // Reactions Weekly;Sep2015, Vol. 1568 Issue 1, p161 

    The article presents a case study of an adult male patient who developed linear IgA bullous dermatosis (LABD) after starting IV infliximab for ulcerative colitis (UC).

  • Flu like symptoms and deranged liver function tests: 2 case reports.  // Reactions Weekly;10/22/2016, Vol. 1624 Issue 1, p28 

    The article presents case studies of patients who developed flu like symptoms or deranged liver function tests during treatment with infliximab.

  • Infliximab.  // Reactions Weekly;Sep2015, Vol. 1568 Issue 1, p165 

    The article presents case studies of three patients who developed tuberculosis while receiving infliximab.

  • Infliximab.  // Reactions Weekly;Sep2015, Vol. 1568 Issue 1, p162 

    The article presents a case study of a 5-month-old baby boy who developed gram-negative septicaemia following treatment with infliximab.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics